Ampio Pharmaceutical's FDA application for Ampion clinical study to treat COVID-19 ARDS on TV

Friday April 3, 2020 0 comments Tags: Englewood, Ampio Pharmaceuticals, Ampion, Michael Macaluso, FDA, COVID-19, ARDS

ENGLEWOOD -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) announced it was featured on a FOX TV segment titled, "Englewood pharmaceutical company looking to treat COVID-19 patients with anti-inflammatory drug," reported by an affiliated television station in Denver. Ampio_logoUSE

The primary cause of death associated with SARS-Cov-2 ("COVID-19") infection is Acute Respiratory Distress Syndrome (ARDS), and there are no approved treatments for ARDS or COVID-19.

The segment featured Ampio’s application to the FDA to study the treatment of COVID-19 induced ARDS with nebulized Ampion.

To view the FOX video segment visit the link below.

Additional information about the potential suitability of the anti-inflammatory properties of Ampion being used for ARDS is included in a companion white paper summary titled, "Rationale and scientific evidence for the use of Ampion in the treatment of Acute Respiratory Distress Syndrome secondary to SARS-COV-2," provided in the link below.

"The company is exploring options that may enable the completion of the AP-013 study, our Phase 3 clinical trial for the treatment of severe osteoarthritis of the knee, during this COVID-19 pandemic,” said Michael Macaluso, Ampio CEO.

“Simultaneously, we have directed our R&D efforts to explore the possible application of the immunomodulatory and anti-inflammatory properties of Ampion in the most severe and lethal complication of the COVID-19 infected patients: ARDS.

“The FDA has been very responsive, and the company is grateful for the agency's efforts as we work together to study the potential benefits of Ampion in this population."